Global Head of Strategic Alliances, Novartis Institutes for Biomedical Research (NIBR)
Martin is the Global Head of Strategic Alliances for the Novartis Institutes for Biomedical Research (NIBR), the research and early development unit of Novartis, and leads a team that is responsible for creating collaborations with external partners that help advance NIBR’s mission. This encompasses licensing, equity investments, acquisitions and major academic collaborations in areas that cover all disease areas and technologies, from early-stage discovery through clinical proof-of-concept. He has served as Board Observer with Surface Oncology, IFM Therapeutics, Intellia Therapeutics, Arcus Biosciences and Caribou Biosciences.
Previously, Martin was head of NIBR’s Genomics Institute of the Novartis Research Foundation (GNF), a 600-person research site in La Jolla, CA, where he helped advance more than 40 clinical candidates, including 25 programs that progressed to the clinic and 13 NME’s that achieved positive clinical proof of concept. Among these are two FDA-approved drugs (Zykadia™/ceritinib and Odomzo®/sonedegib). Previously, Martin was Director of Discovery Biology at DuPont Pharmaceuticals and spent nine years at Ligand Pharmaceuticals in roles of increasing drug discovery responsibility.
Martin earned his Ph.D. from Harvard University in the laboratory of Jeremy R. Knowles. Prior to his graduate work, he spent a year at the Friedrich-Alexander Universität Erlangen-Nürnberg on a DAAD Fellowship and received his A.B. from Princeton University.